Splenic marginal zone lymphoma natural history, complications and prognosis: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Splenic marginal zone lymphoma}} | {{Splenic marginal zone lymphoma}} | ||
{{CMG}}, {{AE}} {{AS}} | |||
==Overview== | |||
==Prognosis== | |||
Three-quarters of patients survive five or more years; more than half of patients with SMZL survive more than a decade after diagnosis.<ref name="Arcaini2006">{{cite journal|last=Arcaini|first=L.|year=2006|title=Splenic marginal zone lymphoma: a prognostic model for clinical use|journal=Blood|volume=107|issue=12|pages=4643–4649|issn=0006-4971|doi=10.1182/blood-2005-11-4659}}</ref> | |||
Patients who have a hemoglobin level of less than 12 g/dL, a [[lactate dehydrogenase]] level higher than normal, and/or a blood serum [[albumin]] levels of less than 3.5 g/dL are likely to have more an aggressive disease course and a shorter survival.<ref name="Arcaini2006" /> However, even high-risk patients have even odds of living for five years after diagnosis.<ref name="Arcaini2006" /> | |||
Some genetic mutations, such as mutations in ''NOTCH2'', are also correlated with shorter survival. | |||
==References== | ==References== | ||
Line 8: | Line 15: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Disease]] | [[Category:Disease]] |
Revision as of 15:01, 14 January 2016
Splenic marginal zone lymphoma Microchapters |
Differentiating Splenic marginal zone lymphoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Splenic marginal zone lymphoma natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Splenic marginal zone lymphoma natural history, complications and prognosis |
FDA on Splenic marginal zone lymphoma natural history, complications and prognosis |
CDC on Splenic marginal zone lymphoma natural history, complications and prognosis |
Splenic marginal zone lymphoma natural history, complications and prognosis in the news |
Blogs on Splenic marginal zone lymphoma natural history, complications and prognosis |
Directions to Hospitals Treating Splenic marginal zone lymphoma |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
Prognosis
Three-quarters of patients survive five or more years; more than half of patients with SMZL survive more than a decade after diagnosis.[1]
Patients who have a hemoglobin level of less than 12 g/dL, a lactate dehydrogenase level higher than normal, and/or a blood serum albumin levels of less than 3.5 g/dL are likely to have more an aggressive disease course and a shorter survival.[1] However, even high-risk patients have even odds of living for five years after diagnosis.[1]
Some genetic mutations, such as mutations in NOTCH2, are also correlated with shorter survival.